



Kinases and Other Molecular Targets in Cancer: Recent Advances, Therapeutic Opportunities, and Clinical Challenges

Guest Editor:

Dr. Ashleigh Poh

The Olivia Newton-John Cancer
Research Institute, Level 5, ONJ
Centre, 145 Studley Rd,
Heidelberg, VIC 3084, Australia

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

Dear Colleagues,

Kinases play a diverse role in regulating cellular processes, including proliferation, differentiation, and apoptosis. However, deregulation of kinase activity can result in oncogenic changes that enable cellular transformation, tumor development, and metastasis. This may occur due to the acquisition of mutations, constitutive expression and/or amplification, epigenetic alterations, and chromosomal translocations.

Kinase inhibitors have revolutionized the treatment landscape of numerous malignancies, including melanoma and non-small-cell lung cancer. However, these drugs are not curative and only a minority of patients derive durable clinical benefit. For this reason, gaining deeper insights into the immunological and molecular mechanisms that underpin therapeutic resistance to kinase inhibitors remains a prime focus in oncology.

This Special Issue will publish original research and reviews.

Dr. Ashleigh Poh
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)